GE Healthcare Announces Data from Phase III Study of AdreView(TM) in Heart Failure Patients

ORLANDO, Fla.--(BUSINESS WIRE)--GE Healthcare, a unit of General Electric Company (NYSE: GE), presented results from the ADMIRE-HF study at the American College of Cardiology’s 58th Annual Scientific Session in Orlando, Florida today. The study involved a nuclear imaging test utilizing the imaging agent AdreView™ (Iobenguane I 123 injection) in heart failure patients who are at a higher risk for cardiac death, disease progression, or cardiac arrhythmias.